



Flexion Therapeutics, Inc.
 Investor Relations Department
 10 Mall Road
 Suite 301
 Burlington, MA 01803
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: FLXN

Last Trade:	25.66
Trade Time:	4:00 PM ET Dec 13, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	16.51 - 32.25
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Dec 13, 2017*
[Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee](#)
- Dec 11, 2017*
[Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer](#)
- Dec 7, 2017*
[Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Bilateral Osteoarthritis of the Knee](#)
- Dec 6, 2017*
[Flexion Therapeutics to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference](#)
- Dec 4, 2017*
[Flexion Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\) \(4\)](#)

Upcoming Events [\[View all \]](#)

- Dec 14, 2017 8:30 AM ET*
[BMO Capital Markets: Prescriptions for Success Healthcare Conference](#)
- Financials** [\[View all \]](#)
[Third Quarter Financial Results](#)
- Mar 10, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)